Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US

2012 ◽  
Vol 15 (sup2) ◽  
pp. 6-13 ◽  
Author(s):  
Yevgeniy Samyshkin ◽  
Anne-Laure Guillermin ◽  
Jennie H. Best ◽  
Steven C. Brunell ◽  
Adam Lloyd
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
The Us ◽  
Diabetes Patients

scholarly journals A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada

2019 ◽  
Vol 8 (4) ◽  
pp. 229-240 ◽  
Author(s):  
Richard F Pollock ◽  
Kirsi Norrbacka ◽  
Chris Cameron ◽  
Leonardo Mancillas-Adame ◽  
Mark Jeddi
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document